GREENWICH, Conn.--(BUSINESS WIRE)-- Sarissa Capital Management LP today issued the following statement regarding Amarin Corporation plc(AMRN) :

Amarin (AMRN) shareholders have sent a loud and clear message repudiating the incumbent Amarin(AMRN) board. Sarissa thanks fellow shareholders for their support in a resounding victory against the Amarin(AMRN) board. Our estimate is that up to nearly 80% of shareholder votes were in support of Sarissa. As Amarin’s largest shareholder, we are grateful for the opportunity to remake Amarin(AMRN) for the benefit of all shareholders.

Vascepa, the foundation on which Amarin(AMRN) is built, is a tremendous drug that is compelling for patients and payors – a unique proposition for a drug. While there is a lot of work to be done, we remain confident in our ability to leverage Vascepa’s rare and highly beneficial profile to unlock tremendous value for all shareholders.

LET’S GET TO WORK AND FINALLY BEGIN RUNNING AMARIN FOR THE BENEFIT OF ALL SHAREHOLDERS